ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME
Clinical trials for ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME trials appear
Sign up with your email to follow new studies for ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare immune disease: leniolisib trial launches
Disease control OngoingThis study tests a drug called leniolisib in children aged 1 to 6 years who have a rare genetic immune disorder called APDS. The drug aims to control the overactive immune system and reduce swollen lymph nodes. Researchers will monitor safety and how well the drug works over time…
Matched conditions: ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME
Phase: PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare immune disease: drug targets root cause
Disease control OngoingThis study tests a drug called leniolisib in children aged 4 to 11 with APDS, a rare genetic condition that causes a faulty immune system. The goal is to see if the drug is safe and can control the disease by blocking an overactive immune signal. About 15 children will take the d…
Matched conditions: ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME
Phase: PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC